These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 25392320)

  • 1. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
    Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
    Oliveira EM; Simm RF; Dasic G; Morais MM; Perreira SL; Callegaro D
    Arq Neuropsiquiatr; 2015 Sep; 73(9):736-40. PubMed ID: 26352489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
    Melis M; Cocco E; Frau J; Lorefice L; Fenu G; Coghe G; Mura M; Marrosu MG
    Neurol Sci; 2014 Mar; 35(3):401-8. PubMed ID: 23990111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
    Iaffaldano P; Viterbo RG; Trojano M
    J Neurol; 2016 Aug; 263(8):1620-5. PubMed ID: 27260295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
    Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
    Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
    Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
    Smith ME; Stone LA; Albert PS; Frank JA; Martin R; Armstrong M; Maloni H; McFarlin DE; McFarland HF
    Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab.
    Roar M; Illes Z; Sejbaek T
    Mult Scler Relat Disord; 2016 Nov; 10():116-122. PubMed ID: 27919477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.
    González-Suarez I; Rodríguez de Antonio L; Orviz A; Moreno-García S; Valle-Arcos MD; Matias-Guiu JA; Valencia C; Jorquera Moya M; Oreja-Guevara C
    Brain Behav; 2017 Apr; 7(4):e00671. PubMed ID: 28413713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    Raffel J; Gafson AR; Dahdaleh S; Malik O; Jones B; Nicholas R
    PLoS One; 2017; 12(1):e0169546. PubMed ID: 28081190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
    Lanzillo R; Bonavita S; Quarantelli M; Vacca G; Lus G; Amato L; Carotenuto A; Tedeschi G; Orefice G; Brescia Morra V
    Neurol Sci; 2013 Apr; 34(4):521-8. PubMed ID: 22526763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab in the pediatric MS population: results of the Italian registry.
    Ghezzi A; Moiola L; Pozzilli C; Brescia-Morra V; Gallo P; Grimaldi LM; Filippi M; G GC;
    BMC Neurol; 2015 Sep; 15():174. PubMed ID: 26407848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
    Vukusic S; Durand-Dubief F; Benoit A; Marignier R; Frangoulis B; Confavreux C
    Mult Scler; 2015 Jun; 21(7):953-5. PubMed ID: 25305253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.
    Muralidharan KK; Steiner D; Amarante D; Ho PR; Mikol D; Elkins J; Subramanyam M; Nestorov I
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):263-275. PubMed ID: 28251386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.